Bicycle Therapeutics plc (NASDAQ:BCYC) CTO Sells $11,320.10 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) CTO Michael Skynner sold 451 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $25.10, for a total value of $11,320.10. Following the sale, the chief technology officer now directly owns 70,924 shares in the company, valued at $1,780,192.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Bicycle Therapeutics Stock Up 1.6 %

NASDAQ BCYC opened at $25.30 on Friday. The stock’s 50-day moving average price is $24.59 and its 200-day moving average price is $24.57. The company has a quick ratio of 7.19, a current ratio of 7.19 and a debt-to-equity ratio of 0.13. Bicycle Therapeutics plc has a 52 week low of $18.80 and a 52 week high of $33.49. The company has a market capitalization of $760.01 million, a P/E ratio of -6.07 and a beta of 0.73.

Get Bicycle Therapeutics alerts:

Bicycle Therapeutics (NASDAQ:BCYC – Free Report) last posted its quarterly earnings data on Thursday, May 4th. The company reported ($1.30) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.24). Bicycle Therapeutics had a negative return on equity of 44.57% and a negative net margin of 801.45%. The company had revenue of $4.90 million during the quarter, compared to the consensus estimate of $4.34 million. On average, equities research analysts predict that Bicycle Therapeutics plc will post -4.91 earnings per share for the current year.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently made changes to their positions in the business. Candriam S.C.A. grew its position in shares of Bicycle Therapeutics by 10.9% during the first quarter. Candriam S.C.A. now owns 1,303,211 shares of the company’s stock worth $25,514,000 after purchasing an additional 128,000 shares in the last quarter. Sio Capital Management LLC grew its position in shares of Bicycle Therapeutics by 41.5% during the first quarter. Sio Capital Management LLC now owns 967,347 shares of the company’s stock worth $20,575,000 after purchasing an additional 283,922 shares in the last quarter. Armistice Capital LLC purchased a new stake in shares of Bicycle Therapeutics during the first quarter worth about $15,655,000. First Light Asset Management LLC grew its position in shares of Bicycle Therapeutics by 0.4% during the first quarter. First Light Asset Management LLC now owns 699,328 shares of the company’s stock worth $14,875,000 after purchasing an additional 2,896 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its position in shares of Bicycle Therapeutics by 12.9% during the first quarter. Loomis Sayles & Co. L P now owns 643,775 shares of the company’s stock worth $28,249,000 after purchasing an additional 73,728 shares in the last quarter. Hedge funds and other institutional investors own 78.38% of the company’s stock.

Analysts Set New Price Targets

Separately, EF Hutton Acquisition Co. I reissued a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, April 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.44.

Bicycle Therapeutics Company Profile

(Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4.

Recommended Stories

• Five stocks we like better than Bicycle Therapeutics
• MarketBeat Week in Review – 7/3 – 7/7
• Pfizer Just Invested $25 million In This Biotech
• Cracks In The Labor Market? Not Yet, But They’re Coming 
• Levi’s: Buy On The Dip Or Downtrend In Play? 
• Who Wins And Who Loses With China’s Metal Restrictions

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.